What changed
$ISRG — Designs and manufactures robotic surgical systems.
🎯 Q1 FY26 | Rev $3B | EPS $2.50 vs $2.11 🟢 | Margin 30.9%
💡 Consensus expects steady procedure growth and margin expansion, but the market may be underestimating the pace of da Vinci 5 upgrades and Ion adoption. However, the stock already trades at a premium that reflects these positives, leaving limited upside from current levels.
🏢 Business Quality: 9/10 | Valuation: rich
📉 Reward/Risk: Upside 10% to $455 (40x FY26 EPS) vs downside 20% to $330 (30x FY26 EPS). Ratio 0.5:1, unfavorable.
🔮 Catalyst: Q2 2026 earnings (late July): da Vinci 5 placements and procedure growth rate. Key metric: da Vinci 5 system placements >200. Failure signal: procedure growth <15% or margins miss.
💰 Entry: Current price $415 is not attractive. Ideal entry below $370 (35x forward EPS) or on a pullback after a growth scare.
Also in play: $MOH $DHR $TMO $BDX $SYK $NVDA